Global pharma major Lupin Limited (Lupin) announced the launch of the United States Food and Drug Administration (FDA) approved Turqoz (norgestrel and ethinyl estradiol) tablets USP, 0.3 mg/0.03 mg.
Turqoz (norgestrel and ethinyl estradiol) tablets USP, 0.3 mg/0.03 mg is the generic equivalent of Lo/Ovral-28 (norgestrel and ethinyl estradiol) tablets, 0.3 mg/0.03 mg of Wyeth Pharmaceuticals LLC and is a contraceptive drug indicated to prevent pregnancy.
Norgestrel and ethinyl estradiol tablets USP (RLD: Lo/Ovral-28) had estimated annual sales of USD 33 million in the US (IQVIA MAT October 2023).
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the US, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
